Advertisement

Topics

Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal

06:50 EDT 5 Jul 2017 | FinanzNachrichten

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) announced Wednesday that a Phase 3 study evaluating the safety and efficacy of adjuvant Opdivo in resected high-risk melanoma patients met ...

Original Article: Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...